Based on our Pharmacor Ovarian Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled How Will Targeted Therapies Entering the Ovarian Cancer Drug Market Impact Physician Prescribing?

Date & Time
Recorded live on Tuesday, June 28, 2011

This 15-minute analyst call, presented by Decision Resources Analyst Amy Duval, M.Res, will answer the following questions:

• Following the updated results of the ICON7 study and new data presented from the OCEANS Phase III trial, what are physicians' perceptions regarding Genentech/Roche/Chugai's Avastin in ovarian cancer?
• How have clinical trial results of PARP inhibitors in breast cancer affected oncologists' opinions of these agents in ovarian cancer, and what is the potential for PARP inhibitors in ovarian cancer treatment?
• Which emerging agents are most anticipated by oncologists, and how will the uptake of these agents affect market dynamics?

This analyst call was held on June 28, 2011. Contact us to learn how you can purchase this service and access the recorded event.

Click here to view the invite.